Drug Trial Radar · NCT05599815
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2023
Primary completion
May 2023
Study completion May 2023
Sponsor
- Lead sponsor
- Aldeyra Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
Conditions
- Nephrotic Syndrome
Interventions
ADX-629Drug
ADX-629 (250 milligrams) administered twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event (AE) QueryTime frame: From Day 1 to Day 90
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Amicis Research Center - Northridge
Northridge, California
University of Colorado
Aurora, Colorado
South Florida Research Institute
Lauderdale Lakes, Florida
Emory University - Pediatric Nephrology
Atlanta, Georgia
ClinCept, LLC
Bremen, Georgia
Northwest Louisiana Nephrology
Shreveport, Louisiana
Nevada Kidney Disease Hypertension Center (NKDHC)
Las Vegas, Nevada
East Carolina University - Nephrology
Greenville, North Carolina
The Ohio State University (OSU) Wexner Medical Center
Columbus, Ohio
University of Toledo Medical Center
Toledo, Ohio
Southern Utah Kidney and Hypertension Center
St. George, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.